The genetic background of pediatric acute myeloid leukemia (AML) does not fit with classification systems developed for adult AML. This study investigates the genetic background of pediatric AML and proposes a genomic framework for improved classification and risk stratification based on the driver alterations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 24, 103–112 (2018). This paper describes the comprehensive genetic background of pediatric AML, highlighting the differences from adult AML.
Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36, 1703–1719 (2022). This paper describes the updates of the WHO classification in 2022.
Umeda, M. et al. Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia. Blood Cancer Discov. 3, 194–207 (2022). This paper first reported UBTF tandem duplication as a subtype-defining gene alteration enriched in pediatric AML.
Montefiori, L. E. et al. Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia. Cancer Discov. 11, 2846–2867 (2021). This paper comprehensively characterized leukemia with BCL11B structural variants.
Pollard, J. A. et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the Children’s Oncology Group Protocol AAML1031. J. Clin. Oncol. 40, 2023–2035 (2022). This paper reported the results of the AAML1031 phase 3 clinical trial.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Umeda, M. et al. A new genomic framework to categorize pediatric acute myeloid leukemia. Nat. Genet. https://doi.org/10.1038/s41588-023-01640-3 (2024).
Rights and permissions
About this article
Cite this article
New genomic classification of pediatric acute myeloid leukemia. Nat Genet 56, 202–203 (2024). https://doi.org/10.1038/s41588-023-01639-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-023-01639-w
